• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

210829-30-4 (Gemcitabine (elaidate))

1

Identification

Gemcitabine (elaidate) Gemcitabine (elaidate)
Name Gemcitabine (elaidate)
Formula C27H43F2N3O5
MW 527.6442
CAS No. 210829-30-4
EINECS
Smiles O[[email protected]@H](C(F)(F)[[email protected]](N1C(N=C(C=C1)N)=O)O2)[[email protected]]2COC(CCCCCCC/C=C/CCCCCCCC)=O
Synonyms CP-4126;CO-101;Gemcitabine 5'-elaidate
InChI InChI=1S/C27H43F2N3O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-23(33)36-20-21-24(34)27(28,29)25(37-21)32-19-18-22(30)31-26(32)35/h9-10,18-19,21,24-25,34H,2-8,11-17,20H2,1H3,(H2,30,31,35)/b10-9+/t21-,24-,25-/m1/s1
2

Introduction

Gemcitabine elaidate, also known as CO-101 and CP-4126, is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.

Background Information

Gemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. ......by AdooQ BioScience, LLC
Gemcitabine elaidate (also known as CO-101; CP-4126) is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by est ......by BOC Sciences
Gemcitabine elaidate, also known as CO-101 and CP-4126, is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity. Upon hydrolysis intracellularly by esterases, the prodrug gemcitabine is converted into the active metabolites difluorodeoxycytidine di- and tri-phosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. ......by MedKoo Biosciences, Inc.
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white Solid EBNumber:EB000016836

Storage condition

4°C by MedChemexpress Co., Ltd.
Storage condition:Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). Stock solution storage:0 - 4 C for short term (days to weeks), or -20 C for long term (months). Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. by MedKoo Biosciences, Inc.

Solubility

10 mM in DMSO by CHEMSCENE, LLC
10 mM in DMSO by MedChemexpress Co., Ltd.
Soluble in DMSO, not in water by MedKoo Biosciences, Inc.
5

Mechanism and Indication

6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
Gemcitabine (elaidate) Clavis Pharma Solid Tumors 2008/10/22 Phase 1 Clinical
Gemcitabine (elaidate) Clavis Pharma Advanced Adenocarcinoma of Pancreas 2009/6/3 Phase 2 Clinical
Gemcitabine (elaidate) - Phase 2
7

Safety Data of Gemcitabine (elaidate)

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AdooQ BioScience, LLC USA
Ark Pharm, Inc. USA
BOC Sciences
Biochempartner Co., Ltd China
CHEMSCENE, LLC 5mg/USD126();10mg/USD174() USA
Carbosynth Limited 500mg/USD2500()
Clearsynth Labs Limited 500mg/USD4200() India
MedChemexpress Co., Ltd. 5mg/USD126();10mg/USD174() USA
MedKoo Biosciences, Inc. 10mg/USD150() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 5mg/USD126();10mg/USD174() China
10

Related Products

Other Forms of 210829-30-4

Name CAS No Formula MW
Gemcitabine (Hydrochloride) 122111-03-9 0.0
Gemcitabine 95058-81-4 C9H11F2N3O4 263.2

Recommended Compounds in Nucleoside Antimetabolite/Analog Autophagy

Name CAS No Formula MW
5-BrdU 59-14-3 C9H11BrN2O5 307.1
Vidarabine 5536-17-4 C10H13N5O4 267.24
Adenosine 58-61-7 C10H13N5O4 267.24
Carmofur 61422-45-5 C11H16FN3O3 257.26
Cytidine 65-46-3 C9H13N3O5 243.22
Merimepodib 198821-22-6 C23H24N4O6 452.46
Floxuridine 50-91-9 C9H11FN2O5 246.19
Dacarbazine 4342-03-4 C6H10N6O 182.18
Tipiracil (hydrochloride) 183204-72-0 C9H12Cl2N4O2 279.12
Trifluorothymidine 70-00-8 C10H11F3N2O5 296.2
Orotic acid 65-86-1 C5H4N2O4 156.1
Nelarabine 121032-29-9 C11H15N5O5 297.27
6-Mercaptopurine 50-44-2 C5H4N4S 152.18
LY2334737 892128-60-8 C17H25F2N3O5 389.39
Cytarabine (hydrochloride) 69-74-9 C9H14ClN3O5 279.68
Cytarabine 147-94-4 C9H13N3O5 243.22
Tegafur 17902-23-7 C8H9FN2O3 200.17
Fludarabine 21679-14-1 C10H12FN5O4 285.23
Triciribine 35943-35-2 C13H16N6O4 320.3
TAS-102 733030-01-8 C20H28Cl2F3N7O6 590.38

Recommended Compounds in Same Indication

Name CAS No Formula MW
MSX-122 897657-95-3 C16H16N6 292.34
NKP-1339 197723-00-5 C14H12Cl4N4NaRu 502.14
NLG-919 1402836-58-1
Oprozomib 935888-69-0 C25H32N4O7S 532.61
VITAMIN K1 12001-79-5 C31H46O2 450.7
GLPG0187 1320346-97-1 C29H37N7O5S 595.71
BGB-283 1446090-77-2 C25H17F3N4O3 478.42
Lurbinectedin 497871-47-3 C41H44N4O10S 784.87
D-3263 947257-66-1 C21H31N3O3 373.49
11

Route of Synthesis

12

References

Protocol Reference

13

More Information

Gemcitabine (elaidate)

Tags: buy 210829-30-4 IC50 | 210829-30-4 price | 210829-30-4 cost | 210829-30-4 solubility | 210829-30-4 purchase | 210829-30-4 manufacturer | 210829-30-4 research buy | 210829-30-4 order | 210829-30-4 MSDS | 210829-30-4 chemical structure | 210829-30-4 Storage condition | 210829-30-4 molecular weight | 210829-30-4 mw | 210829-30-4 datasheet | 210829-30-4 supplier | 210829-30-4 cell line | 210829-30-4 NMR | 210829-30-4 MS | 210829-30-4 IR | 210829-30-4 solubility | 210829-30-4 Safe information | 210829-30-4 Qc and Spectral Information | 210829-30-4 Clinical Information | 210829-30-4 Clinical Trial | 210829-30-4 Route of Synthesis | 210829-30-4 storage condition | 210829-30-4 diseases and conditions | 210829-30-4 flash point | 210829-30-4 boiling point | 210829-30-4 melting point | 210829-30-4 storage condition | 210829-30-4 brand